{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:16:14Z","timestamp":1753892174198,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cyclosporine is a potent immunosuppressive drug for various immune-mediated diseases in children. Cyclosporine\u2019s expected therapeutic effect also carries a wide range of side effects. One of the most common and intriguing dermatological side effects is hypertrichosis. However, recent reports have recognized alopecia as a potential adverse effect of cyclosporine. Here, we report a case of a 29-month-old boy diagnosed with aplastic anemia. During cyclosporine therapy, the patient presented with hair loss on the scalp, which and subsequently spread to the eyebrows and eyelashes. The alopecic symptoms were not relieved following topical minoxidil liniment interventions. When the cyclosporine was discontinued, a remarkable improvement was observed in the scalp, with complete hair regrowth. Data concerning cyclosporine from the FDA Adverse Event Reporting System (FAERS) database were extracted from January 2004 to January 2023. Within FAERS, our post-marketing pharmacovigilance analysis detected the reporting association of cyclosporine and alopecia. In monotherapy, cyclosporine-induced alopecia was observed in 118 cases, and tacrolimus-induced alopecia signals were detected in 197 cases. Although the potential mechanism of medication-induced hair loss is unclear, we identified a potential correlation between alopecia and cyclosporine, and it is still necessary to adequately recognize and clinically monitor this paradoxical reaction.<\/jats:p>","DOI":"10.3389\/fphar.2024.1453034","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:32:23Z","timestamp":1724819543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jaad.2023.04.022","article-title":"Medication-induced hair loss: an update","volume":"89","author":"Alhanshali","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2050313X221138452","DOI":"10.1177\/2050313X221138452","article-title":"Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report","volume":"10","author":"Bourkas","year":"2022","journal-title":"SAGE. Open. Med. Case. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/biomedicines11061769","article-title":"Risankizumab: daily practice experience of high need patients","volume":"11","author":"Brunasso","year":"2023","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","article-title":"Alopecia areata: what's new in the epidemiology, comorbidities, and pathogenesis?","volume":"112","author":"Dainichi","year":"2023","journal-title":"J. Dermatol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bjh.13297","article-title":"Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant","volume":"169","author":"Dufour","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B6","unstructured":"2024"},{"key":"B7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jaad.2023.05.022","article-title":"Drug-induced alopecia areata: a systematic review","volume":"90","author":"Ezemma","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fimmu.2019.00588","article-title":"Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications","volume":"10","author":"Flores","year":"2019","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e17685","DOI":"10.1371\/journal.pone.0017685","article-title":"Expression of a constitutively active calcineurin encoded by an intron-retaining mRNA in follicular keratinocytes","volume":"6","author":"Fujimura","year":"2011","journal-title":"PLoS. One."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41375-023-01892-2","article-title":"What causes aplastic anaemia?","volume":"37","author":"Gale","year":"2023","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"933739","DOI":"10.3389\/fphar.2022.933739","article-title":"Population pharmacokinetics of cyclosporine in Chinese pediatric patients with acquired aplastic anemia","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"107420","DOI":"10.1016\/j.intimp.2021.107420","article-title":"Insights into the modulatory role of cyclosporine A and its research advances in acute inflammation","volume":"93","author":"Gui","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2003705","DOI":"10.1371\/journal.pbio.2003705","article-title":"Identifying novel strategies for treating human hair loss disorders: cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles","volume":"16","author":"Hawkshaw","year":"2018","journal-title":"PLoS. Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.tips.2021.02.001","article-title":"Beyond the NFAT horizon: from cyclosporine A-induced adverse skin effects to novel therapeutics","volume":"42","author":"Hawkshaw","year":"2021","journal-title":"Trends. Pharmacol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2007.11.047","article-title":"NFATc1 balances quiescence and proliferation of skin stem cells","volume":"132","author":"Horsley","year":"2008","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e15855","DOI":"10.1111\/dth.15855","article-title":"Association between the cumulative dose of cyclosporine and liver enzyme abnormalities in dermatology patients managed with a low-dose regimen","volume":"35","author":"Kim","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/jid.2014.82","article-title":"NF-\u03baB activity is required for anagen maintenance in human hair follicles in vitro","volume":"134","author":"Kloepper","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jaad.2017.01.060","article-title":"Commonly prescribed medications associated with alopecia","volume":"88","author":"Mounessa","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13555-020-00370-2","article-title":"Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata: a systematic review","volume":"10","author":"Nowaczyk","year":"2020","journal-title":"Dermatol. Ther. (Heidelb)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102926","DOI":"10.1016\/j.jaut.2022.102926","article-title":"Alopecia Areata: case report and review of pathophysiology and treatment with Jak inhibitors","volume":"133","author":"Paggioli","year":"2022","journal-title":"J. Autoimmun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/0974-7753.96101","article-title":"Cosmetically disfiguring side effects of cyclosporine","volume":"4","author":"Panicker","year":"2012","journal-title":"Int. J. Trichology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S12-S17","DOI":"10.1016\/j.jisp.2017.10.014","article-title":"Hair follicle immune privilege revisited: the key to alopecia areata management","volume":"19","author":"Paus","year":"2018","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/1523-1747.ep12392542","article-title":"A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A","volume":"103","author":"Paus","year":"1994","journal-title":"J. Invest. Dermatol."},{"key":"B24","first-page":"365","article-title":"The induction of anagen hair growth in telogen mouse skin by cyclosporine A administration","volume":"60","author":"Paus","year":"1989","journal-title":"Lab. Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"CD006407","DOI":"10.1002\/14651858.CD006407.pub2","article-title":"First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and\/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia","volume":"2013","author":"Peinemann","year":"2013","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/WNL.0000000000012387","article-title":"Carbamazepine-induced acute alopecia areata","volume":"97","author":"Rathore","year":"2021","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"a035436","DOI":"10.1101\/cshperspect.a035436","article-title":"Identifying new substrates and functions for an old enzyme: calcineurin","volume":"12","author":"Roy","year":"2020","journal-title":"Cold. Spring. Harb. Perspect. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3331024221143538","DOI":"10.1177\/03331024221143538","article-title":"Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases series, evaluation of FAERS, and literature review","volume":"43","author":"Ruiz","year":"2023","journal-title":"Cephalalgia"},{"volume-title":"Anagen effluvium in StatPearls","year":"2023","author":"Saleh","key":"B30"},{"key":"B31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/bjh.15066","article-title":"Paediatric amendment to adult BSH Guidelines for aplastic anaemia","volume":"180","author":"Samarasinghe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: a multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J. Autoimmun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1572-0241.2007.01718.x","article-title":"Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease","volume":"103","author":"Sternthal","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3760\/cma.j.cn112140-20210905-00743","article-title":"Chinese guidelines for the diagnosis and treatment of childhood-onset systemic lupus erythematosus","volume":"59","author":"Board","year":"2021","journal-title":"Zhonghua. Er. Ke. Za. Zhi"},{"key":"B35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.biotechadv.2011.03.004","article-title":"Cyclosporin A--a review on fermentative production, downstream processing and pharmacological applications","volume":"29","author":"Survase","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000508782","article-title":"Improvement of psoriasis, psoriatic arthritis, and alopecia universalis during treatment with Tofacitinib: a case report","volume":"12","author":"Todberg","year":"2020","journal-title":"Case. Rep. Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2165\/00002018-199410040-00005","article-title":"Drug-induced hair loss and hair growth. Incidence, management and avoidance","volume":"10","author":"Tosi","year":"1994","journal-title":"Drug. Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.det.2007.01.005","article-title":"Drug reactions affecting hair: diagnosis","volume":"25","author":"Tosti","year":"2007","journal-title":"Dermatol. Clin."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"35","author":"Trautmann","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7534\/j.issn.1009-2137.2015.02.035","article-title":"Effect of compound Zaofan Pill on bone marrow MVD and VEGF of patients with chronic aplastic anemia","volume":"23","author":"Yang","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1453034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T04:32:29Z","timestamp":1724819549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1453034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":40,"alternative-id":["10.3389\/fphar.2024.1453034"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1453034","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"article-number":"1453034"}}